13F Pro Quality Score

22.2/100

Rank #2,647 of 2,879 stocks

View Technology peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

45.3/100

Profitability

8.1/100

Balance Sheet

9.8/100

Earnings Quality

30.0/100

Free Cash Flow

8.3/100

Institutional Flow

73.0/100

Revenue Scale

20.1/100

Dilution Risk

12.5/100

QTRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Quanterix Corp (QTRX), a Technology sector company. 13F Pro's AI-powered ranking engine scores QTRX at 22.2/100 on a 32-signal composite quality model, placing it at rank #2,647 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (8.1) and free cash flow (8.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Quanterix Corp reports quarterly revenue of $36.4M, net income of $-17.5M, free cash flow of $-18.2M. Top institutional holders of QTRX by reported 13-F value include AMERIPRISE FINANCIAL, BlackRock,, Portolan Capital Management,, based on the most recent SEC filings. QTRX trades on the Nasdaq exchange and files with the SEC under CIK 1503274. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate QTRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Quanterix Corp directly from SEC EDGAR. Quanterix Corp's 13F Pro composite quality score has ranged between 8 and 54 since 2021, currently 22.2 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

Fun facts about Quanterix Corp

Quirks, history, and lore behind QTRX — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. life-science technology company · small-cap · listed on Nasdaq · headquartered in Massachusetts.
  • 2
    The Numbers
    Annual revenue in the tens of millions of dollars — this is a company still investing heavily in growth, with operating losses that reflect a classic early-stage biotech-tool play.
  • 3
    The History
    Founded in the 2000s and spun out of academic research, it went public to fund the commercialization of an ultra-sensitive protein detection platform.
  • 4
    The Secret
    Its core technology can detect single molecules of protein in blood — a level of sensitivity orders of magnitude beyond conventional immunoassays like ELISA.
  • 5
    The Lore
    Its Simoa (Single Molecule Array) platform has become a go-to research tool for measuring blood-based biomarkers of neurological disease, including concussion and Alzheimer's.
  • 6
    The Giveaway
    If you've ever read a paper on plasma p-tau or neurofilament light chain, you've probably encountered this company's Simoa HD-X analyzer — the gold standard for catching brain damage in a blood draw.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$36.4M

Net Income

Q1 2026

$-17.5M

Free Cash Flow

Q1 2026

$-18.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+1.1% YoY
$138.9MFY 2025
FY20 $86.4MFY21 $110.6MFY24 $137.4MFY25 $138.9M

Net Income

-178.2% YoY
$-107.2MFY 2025
FY20 $-31.5MFY21 $-55.5MFY24 $-38.5MFY25 $-107.2M

Operating Income

-138.6% YoY
$-125.5MFY 2025
FY20 $-31.6MFY21 $-56.5MFY24 $-52.6MFY25 $-125.5M

EPS (Diluted)

-151.0% YoY
$-2.51FY 2025
FY20 $-1.07FY21 $-1.54FY24 $-1.00FY25 $-2.51

Total Assets

+3.0% YoY
$418.8MFY 2025
FY20 $271.0MFY21 $501.5MFY24 $406.5MFY25 $418.8M

Total Debt

FY 2025
FY20 $15.4MFY21 FY24 FY25

Op. Cash Flow

-119.6% YoY
$-77.2MFY 2025
FY20 $-23.4MFY21 $-47.6MFY24 $-35.2MFY25 $-77.2M

AI Insight: QTRX Financial Trends

Revenue volatility persists with operating losses deepening despite recent growth recovery from Q2 2025 lows.

Revenue declined from $36M in Q3 2024 to $24M in Q2 2025, then recovered to $44M in Q4 2025 before falling to $36M in Q1 2026.

Operating losses widened from $-11M in Q2 2024 to $-41M in Q1 2026, with margin deterioration throughout the period.

Equity declined from $341M in Q2 2024 to $282M in Q1 2026, reflecting cumulative losses.

Operating cash flow turned sharply negative to $-41M in Q3 2025, the worst quarter in the dataset.

Revenue volatility continues with 47% quarter-over-quarter swings between Q2 2025 and Q4 2025.

AI Insight: QTRX Ratio Trends

Quanterix shows severe operational deterioration with operating margin plunging from -31.8% in Q2 2024 to -113.6% in Q1 2026.

Operating margin deteriorated dramatically from -31.8% in Q2 2024 to -113.6% in Q1 2026.

Net profit margin worsened from -21.5% in Q2 2024 to -48.2% in Q1 2026.

Return on invested capital declined from -12.8% in Q2 2024 to -58.6% in Q1 2026.

Return on equity deteriorated from -8.7% in Q2 2024 to -24.9% in Q1 2026.

Operating margin hit worst level of -151.6% in Q2 2025 before partial recovery.

Q4 2025 showed modest improvement across all metrics before Q1 2026 deterioration resumed.

Get alerted when QTRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Quanterix Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put QTRX on your watchlist

Track score changes the day Quanterix Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is QTRX a good stock to buy?

13F Pro's AI-powered analysis of Quanterix Corp (QTRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for QTRX are available on the QTRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own QTRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling QTRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Quanterix Corp's investment landscape.